



Analyzing the Evolving Role of **LIQUID BIOPSIES** Across Cancer Care

IN-PERSON + VIRTUAL
SATELLITE SYMPOSIUM

SATURDAY, JUNE 4, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Benjamin P. Levy, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

WELCOME

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Medical Crossfire®: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care**.

We will begin with a perspective on the expanding applications of liquid biopsies for molecular characterization of solid tumors, as well as detection of malignancies. State-of-the-art approaches for liquid-based testing of lung, breast, and gastrointestinal malignancies will be explored in depth in order to assist you in providing your patients with the optimal treatment approach. The expert faculty will discuss current applications of liquid biopsies for molecular testing in newly diagnosed patients and in assessment of resistance mechanisms. Future applications for liquid biopsies, such as disease assessment following therapy, will also be discussed. Additionally, interactive Medical Crossfire® panels will illustrate clinical considerations and applications of liquid biopsies.

In working together with PER®, we strive to make this activity, along with all PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with solid tumors.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Benjamin P. Levy, MD

Associate Professor, Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

6:30 PM	Registration and Dinner	
7:00 PM	Welcome and Introductions	Benjamin P. Levy, MD
7:05 PM	The Diagnostic Role of Liquid Biopsy and The Importance of Liquid Biopsy in Ongoing Management	David R. Gandara, MD
7:30 PM	Focus on Non-Small Cell Lung Cancer	Benjamin P. Levy, MD
7:45 PM	Interactive Medical Crossfire®, Featuring Audience Question-and-Answer	Moderator: Benjamin P. Levy, MD
7:55 PM	Focus on Breast Cancer	Heather A. Parsons, MD, MPH
8:10 PM	Interactive Medical Crossfire®, Featuring Audience Question-and-Answer	Moderator: Benjamin P. Levy, MD
8:20 PM	Focus on Gastrointestinal Cancers	Aparna R. Parikh, MD, MS
8:35 PM	Interactive Medical Crossfire®, Featuring Audience Question-and-Answer	Moderator: Benjamin P. Levy, MD
8:45 PM	Postsession Survey	
8:50 PM	Question-and-Answer Session	
9:00 PM	Adjourn	

Upcoming PER® Conferences			2022
	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10

 Virtual Conference  In-Person + Virtual Conference

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, pathologists, nurses, and other oncology health care professionals involved in the treatment of patients with cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Outline key features of liquid biopsies and how they differ from conventional biopsies in the diagnosis and monitoring of cancer
- Explain evidence concerning the reliability of existing and emerging liquid biopsy technologies in cancer care
- Evaluate the relevance of multiple forms of liquid biopsy in the biomarker-driven management of multiple common and less common cancer types
- Summarize the latest evidence concerning the use of liquid biopsy and best practices for real-world applications of these tests

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT on Monday, June 6, 2022. To access these materials, please visit <https://gotoper.com/liquid22biop-esyll>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://gotoper.com/liquid22biop-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 4, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Bayer Healthcare Pharmaceuticals, Inc, GRAIL, and NeoGenomics Laboratories.

Thank you for attending **Medical Crossfire®: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care**

To register for upcoming accredited CE live activities
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future
PER® accredited CE activities.

ACTIVITY OVERVIEW

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Shareholder	Other
David R. Gandara, MD	Amgen, AstraZeneca, Genentech, Merck	Adagene (Institutional), AstraZeneca (Institutional), Biotech (Institutional), Guardant Health (Institutional), IO Oncocyte (Institutional), Lilly, Merck, Novartis, OncoHost (Institutional), Roche-Genentech (Institutional),		
Benjamin P. Levy, MD		Amgen, AstraZeneca, Daiichi Sankyo Eli Lilly, Genentech, Janssen, Marati, Merck, Novartis, Pfizer, Takeda		
Aparna R. Parikh, MD, MS		Biofidelity, Checkmate Pharmaceuticals, Eli Lilly, FMI, Genconn, Guardant and Abbvie, Inivata, Natera, Pfizer, Value Analytics Lab	Equity C2i Genomics, XGenomes	DSMC for a Roche study and has received research funding to the Institution from BMS, Daiichi Sankyo, Genentech, Mirati, Natera, Novartis, PMV Pharmaceuticals, Plexxicon, PureTech, and Takeda.
Heather A. Parsons, MD, MPH	Puma Biotechnology (research support to institute)			

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer


This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Experience
the new
gotoper.com



Streamlining
education
for the busy
clinician



Program Chair



Benjamin P. Levy, MD

Associate Professor, Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Benjamin P. Levy, MD, is an associate professor at Johns Hopkins School of Medicine and the clinical director of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center. Previously, he was medical director of Thoracic Oncology at Mount Sinai Health Systems and associate director of its Cancer Clinical Trials Office. A physician-scientist, he leads global immunotherapy trials that evaluate checkpoint inhibitors with novel combination strategies while remaining interested in the therapeutic value of repurposed therapies, like metformin in lung cancer, and the genetic alterations that predict sensitivity to such agents. Dr. Levy has played an integral role on several ASCO committees and currently serves as associate editor of its University Committee, whose mission is to develop and distribute web-based educational content to oncologists around the country. He recently completed a second term on the editorial board for the Journal of *Clinical Oncology* and serves as an ad hoc reviewer for journals like *Clinical Lung Cancer* and *The Oncologist*. He is one of 15 oncologists in the US who are part of the ASCO Leadership Development Program, whose mission is to identify and develop future ASCO leaders. In addition, he serves on the ALLIANCE Respiratory Committee, the IASLC Staging Committee, and the IASLC Career Development & Fellowship Committee.

Faculty



David R. Gandara, MD

Professor of Medicine Emeritus
Co-Director, Center for Experimental Therapeutics in Cancer
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Adjunct Clinical Professor, Translational and Clinical Research Program, University of Hawaii Cancer Center
Chief Medical Officer, International Society of Liquid Biopsy
Sacramento, CA

David R. Gandara, MD, is Professor of Medicine Emeritus at the University of California, Davis, and both director of Thoracic Oncology and senior advisor to the director at UC Davis Comprehensive Cancer Center. He was recently appointed chief medical officer of the International Society of Liquid Biopsy (ISLB). He is an internationally renowned clinician-scientist and lung cancer specialist who has published more than 450 peer-reviewed papers. Currently the principal investigator in a number of trials, he has led many notable research projects in lung cancer, including early therapeutics trials, cooperative group trials, and multi-institutional translational science projects. Dr. Gandara has received many honors, including the lifetime Scientific Award from the International Association for Study of Lung Cancer, the Team Science Award from the Addario Lung Cancer Foundation, the ISLB Trajectory Achievement Award, and the Giants of Cancer Care Award in lung cancer. He is a past editor-in-chief of *Clinical Lung Cancer*, served as IASLC president from 2009-2011 and treasurer from 2013-2017, and is a former ASCO secretary-treasurer and board member.

**Aparna R. Parikh, MD, MS**

Assistant Professor of Medicine, Harvard Medical School
Director, of the MGH Cancer Center's Global Cancer Care Program
Massachusetts General Hospital Cancer Center
Tucker Gosnell Center for Gastrointestinal Malignancies
Termeer Center for Targeted Therapies
Boston, MA

Aparna R. Parikh, MD, MS, is an expert in gastrointestinal cancers who focuses on young adults with colorectal cancer and patients with pancreatic cancer. She sits on the NCCN guidelines committee for colorectal cancer, leads many of the clinical trials in GI oncology for patients with colorectal and pancreatic cancer, and brings novel agents to the clinic. Dr. Parikh works closely with the Corcoran and Ting labs at the MGH Cancer Center and leads the liquid biopsy efforts for the GI oncology group. An international authority on the subject, she helps to develop liquid biopsies in residual disease after surgery to understand response to treatment and drug resistance. She is also passionate and knowledgeable about cancer care in low- and middle-income countries and does work that supports access, equity, and education in such nations.

**Heather A. Parsons, MD, MPH**

Professor, Medicine, Harvard Medical School
Physician, Susan F. Smith Center for Women's Cancers
Dana-Farber Cancer Institute
Boston, MA

Heather A. Parsons, MD, MPH, is a physician at Dana-Farber Cancer Institute, an associate physician at the Brigham and Women's Hospital, and an instructor in medicine at Harvard Medical School. She is a clinical translational investigator whose focus is developing diagnostics for patients with breast cancer. Her specific research interest is the use of genomics-based biomarkers and circulating tumor DNA (ctDNA) in the care of these patients, and she has led studies in metastatic and early stage disease investigating ctDNA use. Her research is supported by an NCI K08 Award, the Susan G. Komen Foundation, and the Gateway Foundation for Cancer Research. She is the recipient of a Conquer Cancer Foundation Young Investigator Award. Dr. Parsons has an MPH from the Johns Hopkins Bloomberg School of Public Health and an MD from Drexel University College of Medicine, where she was inducted into the AOA Honor Medical Society. She completed an Osler Medical Residency and a fellowship in medical oncology at The Johns Hopkins Hospital.



ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC

40th Annual
CFS®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022
New York Marriott Marquis • New York, NY
In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.

 **100** EXPERT
FACULTY
MEMBERS
 **25** TUMOR
TYPES
 **3** DAYS
 **1** MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com